Filtered By:
Vaccination: Measles Vaccine
This page shows you your search results in order of date. This is page number 12.
Order by Relevance | Date
Total 1232 results found since Jan 2013.
An interregional measles outbreak in Spain with nosocomial transmission, November 2017 to July 2018
Euro Surveill. 2023 Apr;28(17). doi: 10.2807/1560-7917.ES.2023.28.17.2200634.ABSTRACTGiven sustained high vaccination coverage and enhanced surveillance for measles, Spain has been free of endemic measles transmission since 2014, achieving elimination certification from the World Health Organization in 2017. In November 2017, measles was introduced through an imported case travelling to the Valencian Community, causing an interregional outbreak. Here, we describe the outbreak using data reported to the national epidemiological surveillance network. The outbreak involved 154 cases (67 males, 87 females) notified in four reg...
Source: Euro Surveill - April 27, 2023 Category: Infectious Diseases Authors: Despina Pampaka Noem í López-Perea Aurora Fern ández-García Isabel Huertas-Zarco Maite Castellanos-Mart ínez Katja Villatoro-Bongiorno Javier Roig-Sena Nuria Torner Mar ía Mar Mosquera Juan Emilio Echevarr ía Joaquim Ferras Prats Josefa Masa-Calles Source Type: research
Immunogenicity of measles-rubella vaccine administered under India's Universal Immunization Programme in the context of measles-rubella elimination goal: A longitudinal study
CONCLUSIONS: MR vaccine administered below one year of age under the UIP resulted in seroprotection against rubella and measles in a large majority of children. Furthermore, its second dose resulted in seroprotection of all children. The current MR vaccination strategy of two doses, out of which the first is to be given to infants below one year of age, appears robust and justifiable among Indian children.PMID:37102515 | DOI:10.4103/ijmr.IJMR_4113_20
Source: The Indian Journal of Medical Research - April 27, 2023 Category: Biomedical Science Authors: Santosh Kumar Verma Dheeraj Shah Aaradhana Singh Praveen Kumar Singh Shukla Das Piyush Gupta Source Type: research
Future perspectives of emerging novel drug targets and immunotherapies to control drug addiction
This article's main highlight is discussing the drug targets of SUDs and their associated mechanisms. Importantly, we have also discussed the scope of prophylactic measures to eliminate drug dependence.PMID:37099943 | DOI:10.1016/j.intimp.2023.110210
Source: International Immunopharmacology - April 26, 2023 Category: Allergy & Immunology Authors: Jonaid Ahmad Malik Javed N Agrewala Source Type: research
Measles, mumps, and rubella revaccination in children after completion of chemotherapy and hematopoietic stem cell transplantation: a single-center prospective efficacy and safety analysis
CONCLUSIONS: MMR revaccination is immunogenic for the population. We suggest periodic monitoring of antibody titers, in addition to a booster vaccination, although the optimal timing of booster vaccination remains to be investigated further.PMID:37087716 | DOI:10.1007/s12519-023-00721-x
Source: World Journal of Pediatrics : WJP - April 23, 2023 Category: Pediatrics Authors: Min Wang Qing Yuan Peng-Fei Deng Yi Fei Hua Zhang Fen Zhou Wen-Juan Chen Qing Cao Jing Chen Yi-Jin Gao Source Type: research
Cross sectional survey of Varicella-Zoster virus and measles seropositivity in people living with HIV in a Parisian suburb and a review of current immunization guidelines
This study highlights the absence of specific risk factors for VZV and measles seronegativity in PLWHA and supports the importance of routine screening, in order to increase immunization rates and reduce risk of complications.PMID:37085454 | DOI:10.1016/j.vaccine.2023.03.058
Source: Vaccine - April 21, 2023 Category: Allergy & Immunology Authors: A Kolakowska S égolène Brichler H éloise Delagrèverie Julie Marin Ahmed-Chakib Alloui Johann Cailhol Source Type: research
Safety of Measles-Mumps-Rubella booster vaccination in patients with juvenile idiopathic arthritis: A long-term follow-up study
CONCLUSION: MMR booster vaccination was safe and did not worsen disease activity during long-term follow-up in a large cohort of JIA patients being treated with both csDMARDs and biological DMARDs.PMID:37032229 | DOI:10.1016/j.vaccine.2023.03.074
Source: Vaccine - April 9, 2023 Category: Allergy & Immunology Authors: Mohamad Hamad Saied Joeri W van Straalen Sytze de Roock Gerrie C J de Joode-Smink Joost F Swart Nico M Wulffraat Marc H A Jansen Source Type: research
